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neck fracture) and the Hungarian Diagnosis Related Groups.
Patients with polytrauma or severe comorbidities were excluded.
Our retrospective analysis includes patients under 60 with
femoral neck fracture identiﬁed with Social Security Identiﬁca-
tion number (TAJ) and discharged in 2000. RESULTS: A total
of 518 patients met the selection criteria and 23.7% of them (N
= 123) had impaired ability to work. The proportion of patients
with impaired ability to work was 41.3% in patients with further
treatment, 50% in patients with secondary prosthesis and 20%
in patients with one deﬁnitive treatment. The proportion of
patients with impaired ability to work according to the method
of primary surgery was 27.1% in arthroplasty, 23.7 in screw ﬁx-
ation and 20.6% in DHS. A total of 16.3% of disabled patients
received rehabilitation treatment. The proportion of disabled
patients increased in higher age groups. We found higher than
national average disability ratio in regions with higher unem-
ployment rate and lower employment rate. CONCLUSIONS:
We found higher impaired ability to work ratio in patients with
complications receiving further treatment and in arthroplasty. In
order to reduce the impaired ability to work, the sick-pay period
should be used more efﬁciently. The frequency of impaired ability
to work is not only a health related problem but it is an effect
of social and economic processes.
OSTEOPOROSIS—Health Care Use & Policy Studies
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OBJECTIVES: Approximately eight million women and two
million men in the U.S. suffer from osteoporosis, a disease that
causes over 1.5 million fractures each year. The cost to Medic-
aid for anti-osteoporosis medications topped $85 million in the
ﬁrst quarter of 2004. The objective of this study is to analyze
price, cost, utilization, and market shares of oral anti-osteo-
porosis medications in U.S. Medicaid programs, with the speciﬁc
purpose of assessing interbrand competition in a tightly oligop-
olistic market. METHODS: There are ﬁve oral medications for
osteoporosis, including Didronel® (etidronate), Skelid® (tilu-
dronate), Actonel® (risedronate), Fosamax® (alendronate), and
Evista® (raloxifene). Data from the First DataBank® were used
to calculate the monthly Average Wholesale Price (AWP) per
daily dose for each drug over the period 1990–2004. Data from
the National Medicaid Pharmacy claims were used to calculate
quarterly drug prescriptions, market shares, and reimbursements
over essentially the same time period. RESULTS: The three most
frequently prescribed drugs are alendronate (utilization reached
600,000 scripts in the 1st quarter 2004); risedronate whose use
increased from 90 scripts in the 2nd quarter 1999 to 400,000 in
the 1st quarter 2004; and raloxifene with utilization of 190,000
scripts in the 1st quarter 2004. Each of these drugs has an AWP
per daily dose in the $2.00 to $4.00 range. Interestingly, the
Medicaid cost per prescription for risedronate decreased from
$300 in 1999 to $80 in 2004. Though not widely prescribed, the
AWP for tiludronate is much higher than for its competitors at
$15.00 per daily dose. CONCLUSIONS: There is no indication
that market shares or prices of branded medications are respond-
ing to new entry in the anti-osteoporosis drug market. Move-
ment in prices and utilization are driven much more by dosage
and compliance issues.
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OBJECTIVE: To examine the trend in clinical management of
patients with fragile fractures before and after the implementa-
tion of the Health Plan Employer Data and Information Set
(HEDIS) osteoporosis measure. METHODS: Two cohorts of
Medicare Beneﬁciaries with continuous enrollment for at least
18 months and a fracture during the measurement year and no
use of osteoporosis medication or BMD screening in the pre-
ceding 12 months were identiﬁed in the MarketScan Medicare
Supplemental and COB database for the measurement years
2000–2005. Per HEDIS, each measurement year began on July
1st of the preceding year and continues through June 30th of the
measurement year. The ﬁrst cohort consisted of women aged 67
and older, while the second cohort consisted of men and women
aged 65 and older. Fractures were identiﬁed according to HEDIS
deﬁnitions. Clinical management was assessed by the presence of
a claim for BMD screening and/or a prescription for a bisphos-
phonate or other osteoporosis-speciﬁc medication in the year fol-
lowing the fracture. Adjusted rates of change in screening and
treatment were estimated using multivariate logistic regression.
RESULTS: In the measurement year 2000, 8.4% of Cohort 1
underwent BMD screening and 11.2% received pharmacologi-
cal treatment. For Cohort 2, the rates were 6.5% and 8.3%,
respectively. By 2005, BMD screening had increased by 21% and
treatment increased by 15% for Cohort 1. For Cohort 2, the
rates increased by 42% and 22%, respectively. After adjusting
for patient age, sex, fracture location, provider specialty, geo-
graphic region and capitated versus non-capitated health plan,
the rates for screening and treatment had increased by 21% and
15% for Cohort 1, and by 41% and 15% for Cohort 2. CON-
CLUSION: While slow progress has been made in the clinical
management of fracture since the implementation of the HEDIS
osteoporosis measure, there is still an opportunity for signiﬁcant
improvement.
OSTEOPOROSIS—Methods and Concepts
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OBJECTIVES: After the recommended two-month treatment
course of risedronate for the treatment of Paget’s disease,
patients should be followed to assess the need for re-treatment.
We examined real-world treatment patterns and resource uti-
lization in patients treated with risedronate for Paget’s disease.
METHODS: Patients enrolled in a nationally representative,
multi-managed care plan claims database (1998–2004; Phar-
Metrics) with a diagnosis of Paget’s disease (>1 ICD-9 code), >1
risedronate prescription at the Paget’s dose (30mg; daily dosing),
no osteoporosis, and >1 year of follow-up after initial rise-
dronate therapy were identiﬁed. For this cohort, we evaluated:
1) Proportion of patients with risedronate use >1 month after
the recommended treatment regimen in the approved label (i.e.,
additional use); 2) Proportion of patients without risedronate
prescription (i.e., gap) from days 61 to 180, followed by use after
